Low Molecular Weight Heparin Market Size and Growth analysis

report image

Low Molecular Weight Heparin Market Forecast to 2028 - COVID-19 Impact and Global Analysis By Product Type (Enoxaparin, Dalteparin, Tinzaparin, Fraxiparine, Nadroparin, and Others), Packaging (Multi-Vials and Prefilled Syringes), Application [Deep Vein Thrombosis, Acute Coronary Syndrome (ACS), Pulmonary Embolism, and Others], and End User (Hospitals, Clinics, Ambulatory Surgical Centers, and Others), and Geography

Publication Month: Dec 2021 | Report Code: TIPRE00026174 | No. of Pages: 191 | Category: Biotechnology | Status: Published

The low molecular weight heparin market is expected to grow from US$ 3,658.27 million in 2021 to US$ 5,733.96 million by 2028; it is estimated to grow at a CAGR of 6.6% from 2021 to 2028.

Low molecular weight heparin (LMWH) is a class of anticoagulants. They are used to prevent blood clots and to treat venous thromboembolism (deep vein thrombosis and pulmonary embolism) and treat myocardial infarction. LMWHs are defined as heparin salts with an average molecular weight of less than 8,000 Da and in which at least 60% of all chains have a molecular weight of less than 8,000 Da. These are obtained by various methods of fractionation or depolymerization of polymeric heparin. Low molecular weight heparin offers advantages over heparin in that it has better bioavailability and longer half-life, simplified dosing, predictable anticoagulant response, lower risk of HIT, and lower risk of osteoporosis. With a longer half-life and a more predictable anticoagulant response, LMWH can be administered subcutaneously once or twice daily without coagulation monitoring, even when the drug is administered in treatment doses. Most patients do not require coagulation monitoring with LMWH. Key factors driving the growth of the market are the advantages of low molecular weight heparin over unfractionated heparin and the introduction of LMWH anticoagulants across the globe. However, the adverse effects of low molecular weight heparin during treatment hinder the market growth.

Strategic Insights

Report Coverage - Low Molecular Weight Heparin Market
Report CoverageDetails
Market Size Value inUS$ 3,658.27 million in 2021
Market Size Value byUS$ 5,733.96 million by 2028
Growth rateCAGR of 6.6% from 2021 to 2028
Forecast Period2021-2028
Base Year2021
No. of Pages191
No. of Tables111
No. of Charts & Figures80
Historical data availableYes
Segments coveredProduct Type, Packaging, Application, End User, and Geography
Regional scopeNorth America, Europe, Asia Pacific, Middle East & Africa, South & Central America
Country scopeUS, Canada, Mexico, UK, Germany, Spain, Italy, France, India, China, Japan, South Korea, Australia, UAE, Saudi Arabia, South Africa, Brazil, Argentina
Report coverageRevenue forecast, company ranking, competitive landscape, growth factors, and trends
Free Sample Copy Available


The low molecular weight heparin market, by region, is segmented into North America, Europe, Asia Pacific (APAC), the Middle East and Africa (MEA), and South and Central America (SAM). North America held the largest market share in 2021. The market in the region is expected to grow at the fastest pace during the forecast period. Major factors such as the growing burden of diseases, coupled with the rising geriatric population, and the rising number of approvals drive the market growth in the US. According to the Population Reference Bureau Factsheet, the number of Americans aged 65 years and above is projected to grow from 52 million in 2018 to 95 million by 2060, and the 65-and-above age group’s share of the total population is likely to rise from 16% to 23%. The geriatric population is more prone to chronic diseases. Therefore, the heparin market would grow significantly during the forecast period.

Lucrative Regions for Low Molecular Weight Heparin Market

Lucrative Regions for Low Molecular Weight Heparin Market

Get more information on this report :

Market Insights

Advantages of Low Molecular Weight Heparin over Unfractionated Heparin

Low molecular weight heparins (LMWH) can be subcutaneously administered once a day without the need for any supervision. However, the effects of unfractionated heparin (UFH) or standard heparin vary from patient to patient. Therefore, it can only be administered to hospitalized patients under supervision. In addition, the LMWH has more predictable pharmacokinetic properties compared to unfractionated heparin, which allows its administration in fixed doses based on laboratory monitoring, without the need for dose adjustments.

The low molecular weight fractions of heparin have the molecular weight of ~3,500–8,000 Daltons, while unfractionated heparin has a molecular weight of 15,000 Daltons; thus, the former react less with platelets than the latter. Moreover, the LMWH is less likely to induce immune allergic thrombocytopenia, which is a severe side effect of unfractionated heparin (UFH). This condition is often complicated by arterial thrombosis. In addition, properties such as better bioavailability, predictable dose-response, and longer plasma half-life than unfractionated heparin make low molecular weight heparin a preferred choice for anticoagulation therapy. Such advantages of the LMWH over unfractionated heparin are boosting its demand, thereby spurring market growth.

Product Type-Based Insights

The global low molecular weight heparin market, based on product type, is segmented into enoxaparin, dalteparin, tinzaparin, fraxiparine, nadroparin, and others. The enoxaparin segment held the largest share of the market in 2021. However, the dalteparin segment is anticipated to register the highest CAGR in the market during the forecast period.

Low Molecular Weight Heparin Market, by Product Type – 2021 and 2028

Low Molecular Weight Heparin Market, by Product Type – 2021 and 2028

Get more information on this report :

 

Packaging-Based Insights

The global low molecular weight heparin market, based on packaging, is bifurcated into multi-vials and prefilled syringes. In 2021, the multi-vials segment held a larger share of the market. However, the prefilled syringes segment is expected to register a higher CAGR during 2021–2028.

Application-Based Insights

The global low molecular weight heparin market, based on application, is segmented into deep vein thrombosis, acute coronary syndrome (ACS), pulmonary embolism, and others. The deep vein thrombosis segment held the largest share of the market in 2021. However, the acute coronary syndrome (ACS) segment is anticipated to register the highest CAGR in the market during the forecast period.

End Use-Based Insights

The global low molecular weight heparin market, based on end user, has been segmented into hospitals, clinics, ambulatory surgical centers, and others. The hospitals segment held the largest share of the market in 2021. However, the ambulatory surgical centers segment is anticipated to register the highest CAGR in the market during the forecast period.

 

The low molecular weight heparin market players adopt organic strategies, such as product launch and expansion, to expand their footprint and product portfolio worldwide and to meet the growing demand.

Market by Geography

Geographically, the low molecular weight heparin market is segmented into North America (the US, Canada, and Mexico), Europe (France, Germany, the UK, Spain, Italy, and the Rest of Europe), Asia Pacific (China, India, Japan, Australia, South Korea, and the Rest of APAC), Middle East & Africa (Saudi Arabia, the UAE, South Africa, and the Rest of MEA), and South and Central America (Brazil, Argentina, and the Rest of SCAM).

COVID Impacts

The spread of the COVID-19 pandemic has emphasized health data sharing and interoperability under the microscope. The infection of novel coronavirus in children is mild compared to adults, and children are assigned a better prognosis. The interruptions in the supply chain and the massive demand for efficient treatments for COVID-19 have put the health research industry in Asia-Pacific in a crucial position.

Company Profiles

  • Aspen Holdings
  • Changzhou Qianhong Bio-Pharma
  • Leopharma A/S
  • Teva Pharmaceutical Industries Ltd.
  • B. Braun Medical, Inc.
  • Pfizer, Inc.
  • Sanofi
  • Dr. Reddy's Laboratories Limited
  • Abbott
  • Novartis AG                              

The List of Companies - Low Molecular Weight Heparin Market

  1. Aspen Holdings
  2. Changzhou Qianhong Bio-pharma
  3. LEOPHARMA A/S
  4. Teva Pharmaceutical Industries Ltd.
  5. B. Braun Medical Inc.
  6. Pfizer Inc.
  7. Sanofi-Aventis
  8. Dr. Reddy's Laboratories Limited
  9. Abbott
  10. Novartis AG
  • Save and reduce time carrying out entry-level research by identifying the growth, size, leading players and segments in the Low Molecular Weight Heparin market.
  • Highlights key business priorities in order to assist companies to realign their business strategies.
  • The key findings and recommendations highlight crucial progressive industry trends in the global Low Molecular Weight Heparin market, thereby allowing players across the value chain to develop effective long-term strategies.
  • Develop/modify business expansion plans by using substantial growth offering developed and emerging markets.
  • Scrutinize in-depth global market trends and outlook coupled with the factors driving the market, as well as those hindering it.
  • Enhance the decision-making process by understanding the strategies that underpin security interest with respect to client products, segmentation, pricing and distribution
TIPRE00026174
Your data will never be shared with third parties, however, we may send you information from time to time about our products that may be of interest to you. By submitting your details, you agree to be contacted by us. You may contact us at any time to opt-out.

Get the Latest COVID-19 Analysis on this market


Have a Question?

Akshay will walk you through a 15-minute call to present the report’s content and answer all queries if you have any.

Speak to Analyst
Pricing
  • $3000
  • $4550
  • $6550
  • $8550

Sample PDF showcases the content structure and the nature of the information included in the report which presents a qualitative and quantitative analysis.

    Inquire for Discount